{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:03:25Z","timestamp":1770285805284,"version":"3.49.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1016\/j.vaccine.2007.04.071","type":"journal-article","created":{"date-parts":[[2007,5,16]],"date-time":"2007-05-16T12:46:03Z","timestamp":1179319563000},"page":"5433-5440","source":"Crossref","is-referenced-by-count":34,"title":["Vaccinating adolescents against meningococcal disease in Canada: A cost-effectiveness analysis"],"prefix":"10.1016","volume":"25","author":[{"given":"Philippe","family":"De Wals","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Coudeville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Trottier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Chevat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lonny J.","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Van Hung","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2007.04.071_bib1","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","article-title":"Meningococcal disease","volume":"344","author":"Rosenstein","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2007.04.071_bib2","series-title":"Meningococcal disease","first-page":"147","article-title":"Epidemiology of meningococcal disease in Europe and the USA","author":"Jones","year":"1995"},{"key":"10.1016\/j.vaccine.2007.04.071_bib3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1586\/14760584.5.2.269","article-title":"Immunization strategies for the control of serogroup C meningococcal disease in developed countries","volume":"5","author":"De Wals","year":"2006","journal-title":"Expert Rev Vaccines"},{"issue":"RR-7","key":"10.1016\/j.vaccine.2007.04.071_bib4","first-page":"1","article-title":"Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"54","author":"Centers for Disease Control and Prevention","year":"2005","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2007.04.071_bib5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1586\/14760584.5.3.319","article-title":"Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines","volume":"5","author":"Mueller","year":"2006","journal-title":"Expert Rev Vaccines"},{"issue":"Suppl","key":"10.1016\/j.vaccine.2007.04.071_bib6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/01.inf.0000147654.03890.b9","article-title":"Meningococcal vaccines","volume":"23","author":"Danzig","year":"2004","journal-title":"Paed Infect Dis J"},{"key":"10.1016\/j.vaccine.2007.04.071_bib7","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1016\/j.vaccine.2006.03.034","article-title":"A review of vaccine research and development: meningococcal disease","volume":"24","author":"Girard","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.04.071_bib8","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1016\/j.vaccine.2006.02.010","article-title":"Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation","volume":"24","author":"De Wals","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.04.071_bib9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2007.04.071_bib10","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1016\/j.vaccine.2005.03.045","article-title":"Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain","volume":"23","author":"Larrauri","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.04.071_bib11","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1128\/IAI.68.5.2692-2697.2000","article-title":"Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents","volume":"68","author":"Zhang","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2007.04.071_bib12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00006454-200203000-00010","article-title":"Mucosal immune responses to meningococcal conjugate polysaccharide vaccines in infants","volume":"21","author":"Zhang","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2007.04.071_bib13","series-title":"Meningococcal disease","first-page":"71","article-title":"Meningococcal carriage and disease","author":"Cartwright","year":"1995"},{"key":"10.1016\/j.vaccine.2007.04.071_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/aje\/kwi160","article-title":"Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination","volume":"162","author":"Trotter","year":"2005","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2007.04.071_bib15","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(02)08679-8","article-title":"Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination","volume":"359","author":"Maiden","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2007.04.071_bib16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","article-title":"Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis","volume":"326","author":"Ramsay","year":"2003","journal-title":"BMJ"},{"issue":"ACS-3","key":"10.1016\/j.vaccine.2007.04.071_bib17","first-page":"1","article-title":"Statement on conjugate meningococcal vaccine for serogroups A, C, Y and W135","volume":"33","author":"National Advisory Committee on immunization (NACI)","year":"2007","journal-title":"Can Commun Dis Rep"},{"issue":"16","key":"10.1016\/j.vaccine.2007.04.071_bib18","first-page":"121","article-title":"Surveillance of invasive meningococcal disease in Canada, 1995\u20131996","volume":"23","author":"Deeks","year":"1997","journal-title":"Can Commun Dis Rep"},{"issue":"21","key":"10.1016\/j.vaccine.2007.04.071_bib19","first-page":"177","article-title":"Invasive meningococcal disease in Canada, 1 January 1997 to 31 December 1998","volume":"26","author":"Squires","year":"2000","journal-title":"Can Commun Dis Rep"},{"key":"10.1016\/j.vaccine.2007.04.071_bib20","first-page":"17","article-title":"Enhanced surveillance of invasive meningococcal disease in Canada: 1 January 1999 through 31 December 2001","volume":"30","author":"Squires","year":"2004","journal-title":"Can Commun Dis Rep"},{"key":"10.1016\/j.vaccine.2007.04.071_bib21","unstructured":"Lorange M, Jett\u00e9 L. Surveillance des infections envahissantes \u00e0 Neisseria meningitidis. Rapport annuel 2001. Quebec City: Institut national de sant\u00e9 publique, Laboratoire de sant\u00e9 publique du Qu\u00e9bec; 2002. Available at: http:\/\/www.inspq.qc.ca\/pdf\/publications\/113_Neisseriameningitidis2001.pdf."},{"key":"10.1016\/j.vaccine.2007.04.071_bib22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/BF03404126","article-title":"Evaluation of the completeness of reporting of invasive meningococcal disease","volume":"90","author":"Rivest","year":"1999","journal-title":"Can J Public Health"},{"key":"10.1016\/j.vaccine.2007.04.071_bib23","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00006454-200205000-00003","article-title":"Meningococcal infections in children in Arkansas","volume":"21","author":"Stovall","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2007.04.071_bib24","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/322587","article-title":"Complications of meningococcal disease in college students","volume":"33","author":"Erickson","year":"2001","journal-title":"Clin Infect Diseases"},{"key":"10.1016\/j.vaccine.2007.04.071_bib25","series-title":"Infectious diseases of humans: dynamics and control","author":"Anderson","year":"1991"},{"key":"10.1016\/j.vaccine.2007.04.071_bib26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ije\/29.1.180","article-title":"Mathematical modelling of infection and disease due to Neisseria meningitidis and Neisseria lactamica","volume":"29","author":"Coen","year":"2000","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2007.04.071_bib27","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1016\/S0264-410X(02)00161-5","article-title":"Economic analysis of the 1992\u20131993 mass immunization campaign against serogroup C meningococcal disease in Quebec","volume":"20","author":"De Wals","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.04.071_bib28","unstructured":"Meningococcal disease prevention and control strategies for practice-based physicians: a joint statement of the Infectious Diseases and Immunization Committee, Canadian Paediatric Society, and the Committee on Infectious Diseases; 1994\u20131995. Available at http:\/\/www.cps.ca\/english\/statements\/ID\/id96-03.htm."},{"key":"10.1016\/j.vaccine.2007.04.071_bib29","series-title":"Official Disability Guidelines, 2003","year":"2003"},{"key":"10.1016\/j.vaccine.2007.04.071_bib30","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00003086-199404000-00024","article-title":"Long-term cost comparison of major limb salvage using the Ilizarov method versus amputation","volume":"301","author":"Williams","year":"1994","journal-title":"Clin Orthop"},{"key":"10.1016\/j.vaccine.2007.04.071_bib31","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1017\/S0266462300103162","article-title":"The societal costs of severe to profound hearing loss in the United States","volume":"16","author":"Mohr","year":"2000","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.vaccine.2007.04.071_bib32","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0272-6386(03)00404-9","article-title":"Prospective analysis of global costs for maintenance of patients with ESRD","volume":"42","author":"Ploth","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.vaccine.2007.04.071_bib33","unstructured":"Wooten A. Mental retardation services FY2004 statistical summary. Fairfax-Falls Church Community Services Board, 2004. Available at: http:\/\/www.co.fairfax.va.us\/service\/csb\/mrs\/mrsbudata.htm."},{"key":"10.1016\/j.vaccine.2007.04.071_bib34","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0264-410X(01)00254-7","article-title":"Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program","volume":"20","author":"Bos","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.04.071_bib35","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1086\/520303","article-title":"Complications and sequelae of meningococcal disease in Quebec, Canada, 1990\u20131994","volume":"26","author":"Erickson","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2007.04.071_bib36","unstructured":"Ontario Drug Benefit Formulary. Ontario Ministry of Health and Long-Term Care, 2004. Available at: http:\/\/www.health.gov.on.ca\/."},{"key":"10.1016\/j.vaccine.2007.04.071_bib37","unstructured":"Ontario Schedule of Benefits: Physician Services under the Health Insurance Act. Ontario Ministry of Health and Long-Term Care, revised to November 1, 2004."},{"key":"10.1016\/j.vaccine.2007.04.071_bib38","unstructured":"Statistics Canada. Labour force characteristics by age and sex, 2004. Available at http:\/\/www.statcan.ca\/english\/Pgdb\/labor20a.htm."},{"key":"10.1016\/j.vaccine.2007.04.071_bib39","unstructured":"Statistics Canada. Canadian statistics: household size; 2001. Available at http:\/\/www.statcan.ca\/english\/Pgdb\/famil53b.htm."},{"key":"10.1016\/j.vaccine.2007.04.071_bib40","unstructured":"Statistics Canada. Canadian statistics; 2001. Available at http:\/\/www.statcan.ca\/english\/Pgdb\/labor50b.htm."},{"key":"10.1016\/j.vaccine.2007.04.071_bib41","unstructured":"Recommendation from the National Advisory Committee on Immunization (NACI). Immunization schedules, 2006. Available at: http:\/\/www.phac-aspc.gc.ca\/im\/is-cv\/index.html."},{"key":"10.1016\/j.vaccine.2007.04.071_bib42","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.vaccine.2003.09.022","article-title":"Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease","volume":"22","author":"De Wals","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.04.071_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.324.7341.809","article-title":"Modelling cost-effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales","volume":"324","author":"Trotter","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2007.04.071_bib44","series-title":"Comparative review and assessment of key health state measures of the general population","author":"Sturgis","year":"2001"},{"key":"10.1016\/j.vaccine.2007.04.071_bib45","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1086\/340050","article-title":"Influence of serogroup on the presentation, course, and outcome of invasive meningococcal disease in children in the Republic of Ireland, 1995\u20132000","volume":"34","author":"Healy","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2007.04.071_bib46","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0895-4356(02)00448-1","article-title":"The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis. A head-to-head comparison","volume":"55","author":"Oostenbrink","year":"2002","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2007.04.071_bib47","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jama.1996.03540170053032","article-title":"Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group","volume":"276","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2007.04.071_bib48","unstructured":"Statistics Canada. Population estimates based on 1996 Canadian Population Census, 2006. Available at: http:\/\/www.statscan.ca\/."},{"key":"10.1016\/j.vaccine.2007.04.071_bib49","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1001\/jama.292.20.2491","article-title":"Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine","volume":"292","author":"De Wals","year":"2004","journal-title":"JAMA"},{"issue":"ACS-3","key":"10.1016\/j.vaccine.2007.04.071_bib50","first-page":"1","article-title":"Update on meningococcal conjugate vaccines","volume":"31","year":"2005","journal-title":"Can Commun Dis Rep"},{"key":"10.1016\/j.vaccine.2007.04.071_bib51","first-page":"1120","article-title":"Update: Guillain-Barr\u00e9 syndrome among recipients of Menactra\u00ae meningococcal conjugate vaccine\u2014United States, June 2005-September 2006","volume":"55","author":"Woo","year":"2006","journal-title":"MMWR"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07004781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07004781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T09:23:07Z","timestamp":1707902587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X07004781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":51,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S0264410X07004781"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2007.04.071","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}